Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape

Login to access report north_east
Contact sales account_box

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing Phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?

Scope:

  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Allergan
  • Biocon
  • Celltrion
  • Dr. Reddy’s
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Viatris
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Shanghai Henlius Biotech

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Darzalex
  • Enbrel
  • Erbitux
  • Eylea
  • Forteo
  • Herceptin
  • Humira
  • Keytruda
  • Lantus
  • Lucentis
  • Neulasta
  • Neupogen
  • Opdivo
  • Prolia / Xgeva
  • Remicade
  • Rituxan / MabThera
  • Xolair

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
north_east
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS or BRAF mutations…
north_east
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east